Abstract
Purpose
Defining reliable biomarkers is still a challenge in patients with urological tumors. Because miRNAs regulate diverse important cellular processes, these noncoding RNAs are putative molecular candidates. This review intends to give a critical overview about the current state of miRNAs as biomarkers in urological cancers with respect to prognostic stratification as well as for individual treatment selection.
Methods
A comprehensive review of the published literature was conducted focusing at the clinical relevance of miRNAs in tissues and body fluids of prostate, bladder and kidney cancer. Using electronic database, 91 articles, published between 2009 and 2015, were selected and discussed regarding the robustness of miRNAs as valid biomarkers.
Results
A number of miRNAs have been identified with prognostic and predictive relevance in different urologic tumor types. However, the inconsistency of the published results and the lack of multivariate testing in independent cohorts do not allow an introduction into clinical decision making at present.
Conclusion
miRNA-based biomarkers are a promising tool for future personalized risk stratification and response prediction in urological cancers.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adam L, Zhong M et al (2009) miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 15:5060–5072. doi:10.1158/1078-0432.CCR-08-2245
Adam L, Wszolek MF et al (2013) Plasma microRNA profiles for bladder cancer detection. Urol Oncol 31:1701–1708. doi:10.1016/j.urolonc.2012.06.010
Ambs S, Prueitt RL et al (2008) Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68:6162–6170. doi:10.1158/0008-5472.CAN-08-0144
Andrew AS, Marsit CJ et al (2015) Expression of tumor suppressive microRNA-34a is associated with a reduced risk of bladder cancer recurrence. Int J Cancer. doi:10.1002/ijc.29413
Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281–297. doi:10.1016/S0092-8674(04)00045-5
Berkers J, Govaere O et al (2012) A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistance. J Urol 189:1930–1938. doi:10.1016/j.juro.2012.11.133
Brase JC, Johannes M et al (2011) Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 128:608–616. doi:10.1002/ijc.25376
Bray F, Sankila R, Ferlay J, Parkin DM (2002) Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 38:99–166
Bryant RJ, Pawlowski T et al (2012) Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 106:768–774. doi:10.1038/bjc.2011.595
Camussi G, Deregibus MC, Bruno S, Cantaluppi V, Biancone L (2010) Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int 78:838–848. doi:10.1038/ki.2010.278
Carden CP, Sarker D et al (2010) Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? Drug Discov Today 15:88–97. doi:10.1016/j.drudis.2009.11.006
Catto JW, Miah S et al (2009) Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res 69:8472–8481. doi:10.1158/0008-5472.CAN-09-0744
Catto JW, Alcaraz A et al (2011) MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 59:671–681. doi:10.1016/j.eururo.2011.01.044
Cho WC (2010) MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 42:1273–1281. doi:10.1016/j.biocel.2009.12.014
Choi W, Porten S et al (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25:152–165. doi:10.1016/j.ccr.2014.01.009
Chow TF, Youssef YM et al (2010) Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin Biochem 43:150–158. doi:10.1016/j.clinbiochem.2009.07.020
Cummings J, Raynaud F, Jones L, Sugar R, Dive C (2010) Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs. Br J Cancer 103:1313–1317. doi:10.1038/sj.bjc.6605910
Damrauer JS, Hoadley KA et al (2014) Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci USA 111:3110–3115. doi:10.1073/pnas.1318376111
Dip N, Reis ST et al (2012) Stage, grade and behavior of bladder urothelial carcinoma defined by the microRNA expression profile. J Urol 188:1951–1956. doi:10.1016/j.juro.2012.07.004
Drayton RM, Dudziec E et al (2014) Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11. Clin Cancer Res 20:1990–2000. doi:10.1158/1078-0432.CCR-13-2805
Dyrskjot L, Ostenfeld MS et al (2009) Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 69:4851–4860. doi:10.1158/0008-5472.CAN-08-4043
Eble JN, Sauter G, Epstein JI, Sesterhenn IA (2004) World Health Organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs. IARC Press, Lyon
Faragalla H, Youssef YM et al (2012) The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. J Mol Diagn 14:385–392. doi:10.1016/j.jmoldx.2012.02.003
Ferlay J, Autier P et al (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581–592. doi:10.1093/annonc/mdl498
Ferlay J, Steliarova-Foucher E et al (2013) Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 49:1374–1403. doi:10.1016/j.ejca.2012.12.027
Fridman E, Dotan Z et al (2010) Accurate molecular classification of renal tumors using microRNA expression. J Mol Diagn 12:687–696. doi:10.2353/jmoldx.2010.090187
Fritz HK, Lindgren D, Ljungberg B, Axelson H, Dahlback B (2014) The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma. Eur J Cancer 50:1758–1765
Gamez-Pozo A, Anton-Aparicio LM et al (2012) MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients. Neoplasia 14:1144–1152
Gonzales JC, Fink LM et al (2011) Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer 9:39–45. doi:10.1016/j.clgc.2011.05.008
Gowrishankar B, Ibragimova I et al (2014) MicroRNA expression signatures of stage, grade, and progression in clear cell RCC. Cancer Biol Ther 15:329–341. doi:10.4161/cbt.27314
Hagman Z, Haflidadottir BS et al (2013) miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients. Br J Cancer 108:1668–1676. doi:10.1038/bjc.2013.131
Hart M, Nolte E et al (2014) Comparative microRNA profiling of prostate carcinomas with increasing tumor stage by deep sequencing. Mol Cancer Res 12:250–263. doi:10.1158/1541-7786.MCR-13-0230
Hayes J, Peruzzi PP, Lawler S (2014) MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med 20:460–469. doi:10.1016/j.molmed.2014.06.005
Heinzelmann J, Henning B et al (2011) Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol 29:367–373. doi:10.1007/s00345-010-0633-4
Heinzelmann J, Unrein A et al (2014) MicroRNAs with prognostic potential for metastasis in clear cell renal cell carcinoma: a comparison of primary tumors and distant metastases. Ann Surg Oncol 21:1046–1054
Hughes C, Murphy A et al (2006) Topoisomerase II-alpha expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma. J Clin Pathol 59:721–724. doi:10.1136/jcp.2005.029975
Jia AY, Castillo-Martin M et al (2013) A common MicroRNA signature consisting of miR-133a, miR-139-3p, and miR-142-3p clusters bladder carcinoma in situ with normal umbrella cells. Am J Pathol 182:1171–1179. doi:10.1016/j.ajpath.2013.01.006
Jiang X, Du L et al (2015) Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer. Int J Cancer 136:854–862. doi:10.1002/ijc.29041
Kalogirou C, Spahn M et al (2013) MiR-205 is progressively down-regulated in lymph node metastasis but fails as a prognostic biomarker in high-risk prostate cancer. Int J Mol Sci 14:21414–21434. doi:10.3390/ijms141121414
Khella HW, Scorilas A et al (2015) Low expression of miR-126 is a prognostic marker for metastatic clear cell renal cell carcinoma. Am J Pathol 185:693–703
Kim SM, Kang HW et al (2013) Cell-free microRNA-214 from urine as a biomarker for non-muscle-invasive bladder cancer. Korean J Urol 54:791–796
Kneitz B, Krebs M et al (2014) Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. Cancer Res 74:2591–2603. doi:10.1158/0008-5472.CAN-13-1606
Knowles MA (2008) Molecular pathogenesis of bladder cancer. Int J Clin Oncol 13:287–297. doi:10.1007/s10147-008-0812-0
Kobayashi N, Uemura H et al (2012) Identification of miR-30d as a novel prognostic maker of prostate cancer. Oncotarget 3:1455–1471
Kojima K, Fujita Y, Nozawa Y, Deguchi T, Ito M (2010) MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate 70:1501–1512. doi:10.1002/pros.21185
Kozinn SI, Harty NJ et al (2013) MicroRNA profile to predict gemcitabine resistance in bladder carcinoma cell lines. Genes Cancer 4:61–69. doi:10.1177/1947601913484495
Kozomara A, Griffiths-Jones S (2011) miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 39:D152–D157. doi:10.1093/nar/gkq1027
Larne O, Martens-Uzunova E et al (2013) miQ—a novel microRNA based diagnostic and prognostic tool for prostate cancer. Int J Cancer 132:2867–2875. doi:10.1002/ijc.27973
Lee H, Jun SY et al (2014) Expression of miRNAs and ZEB1 and ZEB2 correlates with histopathological grade in papillary urothelial tumors of the urinary bladder. Virchows Arch 464:213–220. doi:10.1007/s00428-013-1518-x
Li T, Li RS et al (2012) miR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer. J Urol 187:1466–1472. doi:10.1016/j.juro.2011.11.082
Lichner Z, Fendler A et al (2013) MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer. Clin Chem 59:1595–1603. doi:10.1373/clinchem.2013.205450
Lin HM, Castillo L et al (2014) Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. Br J Cancer 110:2462–2471. doi:10.1038/bjc.2014.181
Ljungberg B, Campbell SC et al (2011) The epidemiology of renal cell carcinoma. Eur Urol 60:615–621. doi:10.1016/j.eururo.2011.06.049
Lodes MJ, Caraballo M et al (2009) Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 4:e6229. doi:10.1371/journal.pone.0006229
Marchio C, Dowsett M, Reis-Filho JS (2011) Revisiting the technical validation of tumour biomarker assays: how to open a Pandora’s box. BMC Med 9:41. doi:10.1186/1741-7015-9-41
Marin-Aguilera M, Codony-Servat J et al (2012) Identification of docetaxel resistance genes in castration-resistant prostate cancer. Mol Cancer Ther 11:329–339. doi:10.1158/1535-7163.MCT-11-0289
Mavridis K, Stravodimos K, Scorilas A (2013) Downregulation and prognostic performance of microRNA 224 expression in prostate cancer. Clin Chem 59:261–269. doi:10.1373/clinchem.2012.191502
McShane LM, Hayes DF (2012) Publication of tumor marker research results: the necessity for complete and transparent reporting. J Clin Oncol 30:4223–4232. doi:10.1200/JCO.2012.42.6858
Melbo-Jorgensen C, Ness N et al (2014) Stromal expression of MiR-21 predicts biochemical failure in prostate cancer patients with Gleason score 6. PLoS One 9:e113039. doi:10.1371/journal.pone.0113039
Mengual L, Lozano JJ et al (2013) Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer. Int J Cancer 133:2631–2641. doi:10.1002/ijc.28274
Miah S, Dudziec E et al (2012) An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer. Br J Cancer 107:123–128. doi:10.1038/bjc.2012.221
Mitchell PS, Parkin RK et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105:10513–10518. doi:10.1073/pnas.0804549105
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62:1006–1012. doi:10.1016/j.jclinepi.2009.06.005
Moltzahn F, Olshen AB et al (2011) Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res 71:550–560. doi:10.1158/0008-5472.CAN-10-1229
Nguyen HC, Xie W et al (2013) Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate 73:346–354. doi:10.1002/pros.22572
Nordentoft I, Birkenkamp-Demtroder K et al (2012) miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Med Genom 5:40. doi:10.1186/1755-8794-5-40
Ozen M, Creighton CJ, Ozdemir M, Ittmann M (2008) Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27:1788–1793. doi:10.1038/sj.onc.1210809
Patard JJ, Pignot G et al (2011) ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol 60:684–690. doi:10.1016/j.eururo.2011.06.017
Pereira DM, Rodrigues PM, Borralho PM, Rodrigues CM (2013) Delivering the promise of miRNA cancer therapeutics. Drug Discov Today 18:282–289. doi:10.1016/j.drudis.2012.10.002
Petillo D, Kort EJ et al (2009) MicroRNA profiling of human kidney cancer subtypes. Int J Oncol 35:109–114
Petrovich Z, Lieskovsky G, Stein JP, Huberman M, Skinner DG (2002) Comparison of surgery alone with surgery and adjuvant radiotherapy for pT3N0 prostate cancer. BJU Int 89:604–611
Pignot G, Cizeron-Clairac G et al (2013) microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer 132:2479–2491. doi:10.1002/ijc.27949
Porkka KP, Pfeiffer MJ et al (2007) MicroRNA expression profiling in prostate cancer. Cancer Res 67:6130–6135. doi:10.1158/0008-5472.CAN-07-0533
Prior C, Perez-Gracia JL et al (2014) Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma. PLoS One 9:e86263. doi:10.1371/journal.pone.0086263
Puerta-Gil P, Garcia-Baquero R et al (2012) miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol 180:1808–1815. doi:10.1016/j.ajpath.2012.01.034
Ransohoff DF (2004) Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer 4:309–314. doi:10.1038/nrc1322
Ratert N, Meyer HA et al (2013) miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. J Mol Diagn 15:695–705. doi:10.1016/j.jmoldx.2013.05.008
Redova M, Poprach A et al (2012) Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J Transl Med 10:55. doi:10.1186/1479-5876-10-55
Rosenberg E, Baniel J et al (2013) Predicting progression of bladder urothelial carcinoma using microRNA expression. BJU Int 112:1027–1034. doi:10.1111/j.1464-410X.2012.11748.x
Samaan S, Khella HW et al (2015) miR-210 is a prognostic marker in clear cell renal cell carcinoma. J Mol Diagn 17:136–144. doi:10.1016/j.jmoldx.2014.10.005
Sapre N, Hong MK et al (2014) Curated microRNAs in urine and blood fail to validate as predictive biomarkers for high-risk prostate cancer. PLoS One 9:e91729. doi:10.1371/journal.pone.0091729
Schaefer A, Jung M et al (2010) Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 126:1166–1176. doi:10.1002/ijc.24827
Scheffer AR, Holdenrieder S et al (2014) Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? World J Urol 32:353–358. doi:10.1007/s00345-012-1010-2
Schubert M, Spahn M et al (2013) Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer. PLoS One 8:e65064. doi:10.1371/journal.pone.0065064
Segersten U, Spector Y, Goren Y, Tabak S, Malmstrom PU (2014) The role of microRNA profiling in prognosticating progression in Ta and T1 urinary bladder cancer. Urol Oncol 32:613–618. doi:10.1016/j.urolonc.2013.11.001
Selth LA, Townley S et al (2012) Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer 131:652–661. doi:10.1002/ijc.26405
Selth LA, Townley SL et al (2013) Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J Cancer 109:641–650. doi:10.1038/bjc.2013.369
Shen J, Hruby GW et al (2012) Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate 72:1469–1477. doi:10.1002/pros.22499
Shi GH, Ye DW et al (2010) Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells. Acta Pharmacol Sin 31:867–873. doi:10.1038/aps.2010.48
Silva-Santos RM, Costa-Pinheiro P et al (2013) MicroRNA profile: a promising ancillary tool for accurate renal cell tumour diagnosis. Br J Cancer 109:2646–2653. doi:10.1038/bjc.2013.552
Singh PK, Preus L et al (2014) Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. Oncotarget 5:824–840
Slaby O, Redova M et al (2012) Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosomes Cancer 51:707–716. doi:10.1002/gcc.21957
Smith SC, Baras AS et al (2011) A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol 12:137–143. doi:10.1016/S1470-2045(10)70296-5
Spahn M, Joniau S et al (2010a) Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur Urol 58:1–7. doi:10.1016/j.eururo.2010.03.001 (discussion 10–11)
Spahn M, Kneitz S et al (2010b) Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 127:394–403. doi:10.1002/ijc.24715
Staehler M, Haseke N et al (2007) Modern therapeutic approaches in metastatic renal cell carcinoma. EAU-EBU Update Ser 5:26–37. doi:10.1016/j.eeus.2006.08.004
Sturgeon CM, Duffy MJ et al (2008) National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 54:e11–e79. doi:10.1373/clinchem.2008.105601
Szczyrba J, Loprich E et al (2010) The microRNA profile of prostate carcinoma obtained by deep sequencing. Mol Cancer Res 8:529–538. doi:10.1158/1541-7786.MCR-09-0443
Tannock IF, de Wit R et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512. doi:10.1056/NEJMoa040720
Teixeira AL, Ferreira M et al (2014) Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients. Tumour Biol 35:4057–4066. doi:10.1007/s13277-013-1531-3
Tolle A, Jung M et al (2013) Identification of microRNAs in blood and urine as tumour markers for the detection of urinary bladder cancer. Oncol Rep 30:1949–1956. doi:10.3892/or.2013.2621
Torre LA, Bray F et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108. doi:10.3322/caac.21262
True L, Coleman I et al (2006) A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci USA 103:10991–10996. doi:10.1073/pnas.0603678103
Valadi H, Ekstrom K et al (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9:654–659. doi:10.1038/ncb1596
Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT (2011) MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13:423–433. doi:10.1038/ncb2210
Vinall RL, Ripoll AZ, Wang S, Pan CX, deVere White RW (2012) MiR-34a chemosensitizes bladder cancer cells to cisplatin treatment regardless of p53-Rb pathway status. Int J Cancer 130:2526–2538. doi:10.1002/ijc.26256
von Brandenstein M, Pandarakalam JJ et al (2012) MicroRNA 15a, inversely correlated to PKCalpha, is a potential marker to differentiate between benign and malignant renal tumors in biopsy and urine samples. Am J Pathol 180:1787–1797. doi:10.1016/j.ajpath.2012.01.014
Wach S, Nolte E et al (2012) MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int J Cancer 130:611–621. doi:10.1002/ijc.26064
Walter BA, Valera VA, Pinto PA, Merino MJ (2013) Comprehensive microRNA profiling of prostate cancer. J Cancer 4:350–357. doi:10.7150/jca.6394
Wang L, Tang H et al (2009) Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res 69:9490–9497. doi:10.1158/0008-5472.CAN-09-2183
Wang G, Chan ES et al (2012a) Expression of microRNAs in the urine of patients with bladder cancer. Clin Genitourin Cancer 10:106–113. doi:10.1016/j.clgc.2012.01.001
Wang S, Xue S et al (2012b) Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer. Diagn Pathol 7:159. doi:10.1186/1746-1596-7-159
Wang S, Li Q et al (2013) Decreased expression of microRNA-31 associates with aggressive tumor progression and poor prognosis in patients with bladder cancer. Clin Transl Oncol 15:849–854. doi:10.1007/s12094-013-1014-4
Wang XL, Xie HY et al (2014) Increased miR-141 expression is associated with diagnosis and favorable prognosis of patients with bladder cancer. Tumour Biol 36:877–883. doi:10.1007/s13277-014-2656-8
Watahiki A, Macfarlane RJ et al (2013) Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer. Int J Mol Sci 14:7757–7770. doi:10.3390/ijms14047757
Weber JA, Baxter DH et al (2010) The microRNA spectrum in 12 body fluids. Clin Chem 56:1733–1741. doi:10.1373/clinchem.2010.147405
Wiklund ED, Bramsen JB et al (2011) Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 128:1327–1334. doi:10.1002/ijc.25461
Wilt TJ, Brawer MK et al (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203–213. doi:10.1056/NEJMoa1113162
Wu X, Weng L et al (2012) Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One 7:e35661. doi:10.1371/journal.pone.0035661
Wulfken LM, Moritz R et al (2011) MicroRNAs in renal cell carcinoma: diagnostic implications of serum miR-1233 levels. PLoS One 6:e25787. doi:10.1371/journal.pone.0025787
Yamada Y, Enokida H et al (2011) MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci 102:522–529. doi:10.1111/j.1349-7006.2010.01816.x
Yaman Agaoglu F, Kovancilar M et al (2011) Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol 32:583–588. doi:10.1007/s13277-011-0154-9
Yossepowitch O, Eggener SE et al (2007) Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 178:493–499 (discussion 499)
Youssef YM, White NM et al (2011) Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol 59:721–730. doi:10.1016/j.eururo.2011.01.004
Yun SJ, Jeong P et al (2012) Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. Int J Oncol 41:1871–1878. doi:10.3892/ijo.2012.1622
Zabolotneva AA, Zhavoronkov AA et al (2013) A systematic experimental evaluation of microRNA markers of human bladder cancer. Front Genet 4:247. doi:10.3389/fgene.2013.00247
Zaman MS, Shahryari V et al (2012) Up-regulation of microRNA-21 correlates with lower kidney cancer survival. PLoS One 7:e31060. doi:10.1371/journal.pone.0031060
Zen K, Zhang CY (2012) Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev 32:326–348. doi:10.1002/med.20215
Zhai Q, Zhou L et al (2012) Identification of miR-508-3p and miR-509-3p that are associated with cell invasion and migration and involved in the apoptosis of renal cell carcinoma. Biochem Biophys Res Commun 419:621–626. doi:10.1016/j.bbrc.2012.02.060
Zhang HL, Yang LF et al (2011) Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 71:326–331. doi:10.1002/pros.21246
Zhang DZ, Lau KM et al (2014) Cell-free urinary microRNA-99a and microRNA-125b are diagnostic markers for the non-invasive screening of bladder cancer. PLoS One 9:e100793. doi:10.1371/journal.pone.0100793
Zhao A, Li G, Peoc’h M, Genin C, Gigante M (2013) Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol 94:115–120. doi:10.1016/j.yexmp.2012.10.005
Zhao JJ, Chen PJ et al (2014) Up-regulation of miR-630 in clear cell renal cell carcinoma is associated with lower overall survival. Int J Clin Exp Pathol 7:3318–3323
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
We declare that we have no conflict of interest.
Human and animal rights statement
This article does not contain any studies with human participants or animals performed by any of the authors.
Rights and permissions
About this article
Cite this article
Schubert, M., Junker, K. & Heinzelmann, J. Prognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: Where do we stand in biomarker development?. J Cancer Res Clin Oncol 142, 1673–1695 (2016). https://doi.org/10.1007/s00432-015-2089-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-015-2089-9